ArticleFrontiers in pediatrics2026
Developing affordable monoclonal antibodies for LMICs through high performance manufacturing processes and LMIC based commercial manufacturing.
Article in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Monoclonal Antibodies (mAbs) are one of the most effective developments in disease prevention and treatment of the last century. Active treatment and passive immunization with mAbs targeting key antigens represents a promising approach to preventing and mitigating infectious pathogen-caused illness, particularly in Low and Middle-Income Countries (LMICs). While the development of mAbs against infectious disease has lagged behind that of immune disorders and oncology targets, recent efforts against infectious diseases have seen increasing focus with the development of mAbs against RSV, Ebola strains, and SARS-CoV-2, among others. The price for mAb treatment remains out of reach for most patients in middle income countries and nearly all patients in low-income countries. It is therefore clear that a new approach to manufacturing mAbs is needed. Here, high-productivity, high-yield mAb fed-batch production is demonstrated using clonal variants of ZAC-3, a mAb directed against the conserved core/lipid A region of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.